Clinical Trial Update: A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing neoadjuvant everolimus plus letrozole to FEC in ER-positive, HER2-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Everolimus (everolimus)
• FEC
• Letrozole (letrozole)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED